A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma

Blood

Volumn 94, Issue 10, 1999, Pages 3334-3339

  Salven, Petri ^a   Teerenhovi, Lasse ^a   Joensuu, Heikki ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER SURVIVAL; CYTOKINE RELEASE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR GROWTH;

EID: 0033571339     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.10.3334.422k18_3334_3339     Document Type: Article

References (48)

1. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27, 1995
2. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315, 1994
3. Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1:149, 1995
4. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353, 1996
5. Iruela-Arispe ML, Dvorak HF: Angiogenesis: A dynamic balance of stimulators and inhibitors. Thromb Haemost 78:672, 1997
6. Friesel RE, Maciag T: Molecular mechanisms of angiogenesis: Fibroblast growth factor signal transduction, FASEB J 9:919, 1995
7. Bikfalvi A, Klein S, Pintucci G, Rifkin DB: Biological roles of fibroblast growth factor-2. Endocr Rev 18:26, 1997
8. Melder RJ, Koenig GC, Witwer BP, Safabakhsh N, Munn LL, Jain RK: During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 2:992, 1996
9. Hori A, Sasada R, Matsutani E, Naito K, Sakura Y, Fujita T, Kozai Y: Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 51:6180, 1991
10. Wang Y, Becker D: Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med 3:887, 1997
11. Kandel J, Bossy-Wetzel E, Radvanyi F, Klagsbrun M, Folkman J, Hanahan D: Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 66:1095, 1991
12. Fujimoto K, Ichimori Y, Kakizoe T, Okajima E, Sakamoto H, Sugimura T, Terada M: Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma. Biochem Biophys Res Commun 180:386, 1991
13. Dirix LY, Vermeulen PB, Hubens G, Benoy I, Martin M, De Pooter C, Van Oosterom AT: Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol 7:843, 1996
14. Dirix LY, Vermeulen PB, Pawinski A, Prove A, Benoy I, De Pooter C, Martin M, Van Oosterom AT: Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 76:238, 1997
15. Cronauer MV, Hittmair A, Eder IE, Hobisch A, Culig Z, Ramoner R, Zhang J, Bartsch G, Reissigl A, Radmayr C, Thurnher M, Klocker H: Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate. Prostate 31:223, 1997
16. Leunig A, Tauber S, Spaett R, Grevers G, Leunig M: Basic fibroblast growth factor in serum and urine of patients with head and neck cancer. Oncol Rep 5:955, 1998
17. Landriscina M, Cassano A, Ratto C, Longo R, Ippoliti M, Palazzotti B, Crucitti F, Barone C: Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br J Cancer 78:765, 1998
18. Chodak GW, Hospelhorn V, Judge SM, Mayforth R, Koeppen H, Sasse J: Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. Cancer Res 48:2083, 1988
19. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J: Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 86:356, 1994
20. O'Brien TS, Smith K, Cranston D, Fuggle S, Bicknell R, Harris AL: Urinary basic fibroblast growth factor in patients with bladder cancer and benign prostatic hypertrophy. Br J Urol 76:311, 1995
21. National Cancer Institute sponsored study on classification of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 49:2112, 1982
22. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 14:987, 1993
23. Hondermarck H, Courty J, Boilly B, Thomas D: Distribution of intravenously administered acidic and basic fibroblast growth factors in the mouse. Experientia 46:973, 1990
24. Soutter AD, Nguyen M, Watanabe H, Folkman J: Basic fibroblast growth factor secreted by an animal tumor is detectable in urine. Cancer Res 53:5297, 1993
25. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361, 1994
26. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J: Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 150:815, 1997
27. Ribatti D, Vacca A, Nico B, Fanelli M, Roncali L, Dammacco F: Angiogenesis spectrum in the stromaof B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. Eur J Haematol 56:45, 1996
28. Vacca A, Ribatti D, Ruco L, Giacchetta F, Nico B, Quondamatteo F, Ria R, Iurlaro M, Dammacco F: Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br J Cancer 79:965, 1999
29. Dvorak HF, Sioussat TM, Brown LF, Berse B, Nagy JA, Sotrel A, Manseau EJ, Van de Water L, Senger DR: Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med 174:1275, 1991
30. Salven P, Lymboussaki A, Heikkila P, Jaaskela-Saari H, Enholm B, Aase K, von Euler G, Eriksson U, Alitalo K, Joensuu H: Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol 153:103, 1998
31. Hermans J, Krol AD, van Groningen K, Kluin PM, Kluin-Nelemans JC, Kramer MH, Noordijk EM, Ong F, Wijermans-PW: International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 86:1460, 1995
32. Vacca A, Ribatti D, Iurlaro M, Albini A, Minischetti M, Bussolino F, Pellegrino A, Ria R, Rusnati M, Presta M, Vincenti V, Persico MG, Dammacco F: Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis. Int J Clin Lab Res 28:55, 1998
33. Allouche M, Bayard F, Clamens S, Fillola G, Sie P, Amalric F: Expression of basic fibroblast growth factor (bFGF) and FGF-receptors in human leukemic cells. Leukemia 9:77, 1995
34. Menzel T, Rahman Z, Calleja E, White K, Wilson EL, Wieder R, Gabrilove J: Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood 87:1056, 1996
35. Gu XF, Bikfalvi A, Chen YZ, Caen JP, Han ZC: Constitutive and selective expression of basic fibroblast growth factor in human leukaemia cell lines. Eur J Haematol 55:189, 1995
36. Peoples GE, Blotnick S, Takahashi K, Freeman MR, Klagsbrun M, Eberlein TJ: T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: A potential pathologic role. Proc Natl Acad Sci USA 92:6547, 1995
37. Blotnick S, Peoples GE, Freeman MR, Eberlein TJ, Klagsbrun M: T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: Differential production and release by CD4+ and CD8+ T cells. Proc Natl Acad Sci USA 91:2890, 1994
38. Kuwabara K, Ogawa S, Matsumoto M, Koga S, Clauss M, Pinsky DJ, Lyn P, Leavy J, Witte L, Joseph-Silverstein J, Furie MB, Torcia G, Cozzolino F, Kamada T, Stern DM: Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc Natl Acad Sci USA 92:4606, 1995
39. Brunner G, Nguyen H, Gabrilove J, Rifkin DB, Wilson EL: Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells. Blood 81:631, 1993
40. Schulze-Osthoff K, Risau W, Vollmer E, Sorg C: In situ detection of basic fibroblast growth factor by highly specific antibodies. Am J Pathol 137:85, 1990
41. Fujisaki K, Mitsuyama K, Toyonaga A, Matsuo K, Tanikawa K: Circulating vascular endothelial growth factor in patients with colorectal cancer. Am J Gastroenterol 93:249, 1998
42. Kumar H, Heer K, Lee PW, Duthie GS, MacDonald AW, Greenman J, Kerin MJ, Monson JR: Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 4:1279, 1998
43. Salven P, Teerenhovi L, Joensuu H: A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 90:3167, 1997
44. Salven P, Ruotsalainen T, Mattson K, Joensuu H: High pretreatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 79:144, 1998
45. Tempfer C, Obermair A, Hefler L, Haeusler G, Gitsch G, Kainz C: Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet Gynecol 92:360, 1998
46. Standker L, Schrader M, Kanse SM, Jurgens M, Forssmann WG, Preissner KT: Isolation and characterization of the circulating form of human endostatin. FEBS Lett 420:129, 1997
47. Sasaki T, Fukai N, Mann K, Gohring W, Olsen BR, Timpl R: Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. EMBO J 17:4249, 1998
48. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277, 1997